ArticleBMC anesthesiology2025
Analysis of factor concentrates in pediatric patients undergoing living donor liver transplantation: a retrospective, propensity-matched study.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBleeding is a common issue in pediatric living donor liver transplantation (LDLT). Coagulopathy related bleeding can lead to increased morbidity and mortality. There has been limited research on the use of coagulation factor complexes, specifically fibrinogen concentrate (FibC) and prothrombin complex concentrate (PCC), in pediatric LDLT.
methodsPediatric patients who underwent LDLT between March 2019 and December 2024 were identified. Patients who received FibC and PCC were assigned to the F group(n = 103), while those who did not receive these treatments were designated as the C group (n = 272). After 1:1 propensity score matching, 57 patients were included in each group for analysis. The primary endpoint was the need for red blood cell (RBC) transfusion in pediatric patients undergoing LDLT.
resultsThere was no significant difference in the volume of RBC infusion between groups F and C (median [interquartile range]: 550.00 (400.00, 600.00) ml vs. 700.00 (400.00, 750.00) ml [p = 0.281]). In terms of plasma and intraoperative bleeding, group F demonstrated a trend toward lower levels compared to group C; however, there was no significant difference between the two groups. The two groups had no significant difference in intraperitoneal drainage volume or RBC infusion volume 24 h after surgery. Both groups also showed no difference in postoperative outcomes such as mechanical ventilation time, ICU stay, and hospital length of stay. Fibrinogen, PT, and INR levels post-surgery were significantly better in Group F than in Group C. Additionally, the groups had no notable differences in postoperative complications, including thromboses or embolism.
conclusionsThis study indicates that using FibC and PCC was linked to a trend of reducing intraoperative RBC administration and bleeding in pediatric patients undergoing LDLT, although no significant difference was observed. Coagulopathy management strategies emphasizing targeted factor replacement should be a focus for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.